Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

IntroductionThe serine/threonine kinase 17B (STK17B) is involved in setting the threshold for T cell activation and its absence sensitizes T cells to suboptimal stimuli. Consequently, STK17B represents an attractive potential target for cancer immunotherapy.MethodsTo assess the potential of STK17B a...

Full description

Saved in:
Bibliographic Details
Main Authors: Felix Scheuplein, Florian Renner, John E. Campbell, Robert Campbell, Chris De Savi, Jan Eckmann, Holger Fischer, Jie Ge, Luke Green, Peter Jakob, Joseph L. Kim, Caitlin Kinkema, Katie McGinn, Ricardo Medina, Annemarie Müller, Nisha Perez, Emanuele Perola, Yoav Timsit, Tary Traore, Ulrike Hopfer, Stefka Tyanova, Manuel Tzouros, Ruduan Wang, Richard Woessner, Marion Dorsch, James R. Bischoff
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Immunology
Subjects:
DRAK2
STK17B
immunotherapy
small molecule inhibitors
T cells
kinase
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1411395/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1411395/full

Similar Items